載入中
LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment. Similarly, ATH-1020 is also in Phase 1 trials, targeting various neurodegenerative disorders. Furthermore, LeonaBio has an array of earlier-stage compounds in preclinical research. The company, which was originally established as Athira Pharma, Inc., rebranded itself as LeonaBio, Inc. in January 2026. Founded in 2011, its corporate headquarters are situated in Bothell, Washington.
前收盤價
US$6.165
+US$0.415 · +7.22%
盤後
US$6.165
US$0.00 · 0.00%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment. Similarly, ATH-1020 is also in Phase 1 trials, targeting various neurodegenerative disorders. Furthermore, LeonaBio has an array of earlier-stage compounds in preclinical research. The company, which was originally established as Athira Pharma, Inc., rebranded itself as LeonaBio, Inc. in January 2026. Founded in 2011, its corporate headquarters are situated in Bothell, Washington.
日內區間
目前US$6.165
52週區間
目前US$6.165
盤中時間採用ET。市場資料可能有所延遲。
LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment. Similarly, ATH-1020 is also in Phase 1 trials, targeting various neurodegenerative disorders. Furthermore, LeonaBio has an array of earlier-stage compounds in preclinical research. The company, which was originally established as Athira Pharma, Inc., rebranded itself as LeonaBio, Inc. in January 2026. Founded in 2011, its corporate headquarters are situated in Bothell, Washington.
日內區間
目前US$6.165
52週區間
目前US$6.165
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 6808.8萬 USD | — | — | — | 47.9萬 USD |
| 毛利 | −6808.8萬 USD | — | — | — | −47.9萬 USD |
| 研究與開發 | 1750萬 USD | 7068.2萬 USD | 9379萬 USD | 6146.4萬 USD | 4279.4萬 USD |
| 銷售、一般及管理費用 | 1667.8萬 USD | 2609.3萬 USD | 3330.4萬 USD | 3255.2萬 USD | 2122.8萬 USD |
| 營業費用 | 3417.8萬 USD | 1.01億 USD | 1.25億 USD | 1.04億 USD | 6354.3萬 USD |
| 利息收入 | — | 396.2萬 USD | 763.7萬 USD | 321.6萬 USD | 33.7萬 USD |
| 利息支出 | — | — | — | 2431.6萬 USD | 3000 USD |
| 折舊和攤銷 | 97.2萬 USD | 97萬 USD | 96.9萬 USD | 84.5萬 USD | 47.9萬 USD |
| 營業利益 | −1.02億 USD | −1.01億 USD | −1.25億 USD | −1.04億 USD | −6402.2萬 USD |
| 淨利 | −1.06億 USD | −9694萬 USD | −1.18億 USD | −9563.9萬 USD | −5485.3萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$17.50
上漲空間 183.86%AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
